Additionally, Abdelmoemen et al. observed a significant increase in FGL1 levels in NAFLD patients with type 2 diabetes, attributing to accelerated disease progression through enhanced lipid accumulation in the liver [53]. The gene discussed is FGL1; the disease is metabolic dysfunction-associated steatotic liver disease.